Chi­na reg­u­la­tors launch a re­view for BeiGene’s PD-1; PureTech co-founder hops to Long­wood Fund

→ Bei­jing-based BeiGene says that Chi­na’s reg­u­la­to­ry group — the Na­tion­al Med­ical Prod­ucts Ad­min­is­tra­tion of Chi­na — has ac­cept­ed its NDA for their PD-1 check­point …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.